References
- Calvalido J, Wood GA, Mutsaers AJ, Wood D, Sears W, Woods JP. 2016. Comparison of serum cytokine levels between dogs with multicentric lymphoma and healthy dogs. Vet Immunol Immunopathol 182: 106-114. https://doi.org/10.1016/j.vetimm.2016.10.009
- Carmeliet P. 2005. VEGF as a key mediator of angiogenesis in cancer. Oncology 69: 4-10. https://doi.org/10.1159/000088478
- Day MJ, Lucke VM, Pearson H. 1995. A review of pathological diagnoses made from 87 canine splenic biopsies. J Small Anim Pract 36: 426-433. https://doi.org/10.1111/j.1748-5827.1995.tb02769.x
- Frezoulis P, Harper A. 2022. The role of toceranib phosphate in dogs with non-mast cell neoplasia: A systematic review. Vet Comp Oncol 20: 362-371. https://doi.org/10.1111/vco.12799
- Gardner HL, London CA, Portela RA, Nguyen S, Rosenberg MP, Klein MK, Clifford C, Thamm DH, Vail DM, Bergman P, Crawford-Jakubiak M, Henry C, Locke J, Garrett LD. 2015. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. Vet Res 11: 131.
- Goldschmidt MH, Hendrick MJ. 2002. Tumors of the skin and soft tissues, pp. 45-117. In: Meuten DJ (ed.). Tumors in domestic animals. 4th ed. Iowa State University Press. Iowa.
- Hisada Y, Mackman N. 2019. Tissue factor and cancer: regulation, tumor growth, and metastasis. Semin Thromb Hemost 45: 385-395. https://doi.org/10.1055/s-0039-1687894
- Jang JK, Chretin J, Bruyette D, Hu P, Epstein AL. 2015. Phase 1 dose-escalation study with LEC/chTNT-3 and toceranib phosphate (Palladia®) in dogs with spontaneous malignancies. J Cancer Sci Ther 7: 167-174. https://doi.org/10.4172/1948-5956.1000343
- Kim KT, Han SY, Park EH, Jang JS, Roh MH, Lee SW, Jeong JS. 2007. A case of the treatment in an adult with hepatic undifferentiated (embryonal) sarcoma. Korean J Hepatol 13: 96-102.
- Laver T, London CA, Vail DM, Biller BJ, Coy J, Thamm DH. 2018. Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma. Vet Comp Oncol 16: E23-E29. https://doi.org/10.1111/vco.12328
- Milovancev M, Helfand SC, Marley K, Goodall CP, Lohr CV, Bracha S. 2016. Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro. Vet Res 12:85.
- Mitchell L, Thamm DH, Biller BJ. 2012. Clinical and immunomodulatory effects of Toceranib combined with low-dose cyclophosphamide in dogs with cancer. J Vet Intern Med 26: 355-362. https://doi.org/10.1111/j.1939-1676.2011.00883.x
- Nguyen SM, Thamm DH, Vail DM, London CA. 2015. Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol 13: 176-183. https://doi.org/10.1111/vco.12032
- Pan X, Tsimbas K, Kurzman ID, Vail DM. 2016. Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia®) in tumour-bearing dogs: a phase I dose-finding study. Vet Comp Oncol 14: 202-209. https://doi.org/10.1111/vco.12091
- Patnaik AK, Hurvitz AI, Lieberman PH. 1980. Canine hepatic neoplasms: a clinicopathologic study. Vet pathol 17: 553-564. https://doi.org/10.1177/030098588001700504
- Spangler WL, Culbertson MR, Kass PH. 1994. Primary mesenchymal (nonangiomatous/nonlymphomatous) neoplasms occurring in the canine spleen: anatomic classification, immunohistochemistry, and mitotic activity correlated with patient survival. Vet Pathol 31: 37-47. https://doi.org/10.1177/030098589403100105